Sunday 11 October 2026
Export all LLY data to Excel Powerpack
Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
1,179.27
9.67
+0.83%
Follow LLY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 7 | 8 | 9 |
| 96.47% | 101.16% | 107.46% | 102.29% | ||
| 19.33% | 21.59% | 24.54% | 21.97% | ||
ROIC |
25.82% | 26.61% | 30.18% | 26.33% | |
Return on Tangible Assets |
41.61% | 45.79% | 56.50% | 57.79% | |
Average Days of Receivables |
119.52 | 112.87 | 106.99 | 107.56 | |
Free Cash Flow per Share |
10.34 | 10.00 | 13.22 | 20.38 | |
Free Cash Flow |
9,271.80 | 8,972.00 | 11,823.00 | 18,190.00 | |
Capital Expenditures |
(6,790.50) | (7,841.00) | (8,657.00) | (9,893.00) | |
| Other line items | |||||
Cash ROIC |
12.42% | 11.76% | 15.59% | 18.61% | |
Accounts Receivable Turnover |
3.77 | 3.90 | 4.11 | 3.92 | |
Accounts Payable Turnover |
2.82 | 2.57 | 2.93 | 2.60 | |
Inventory Turnover |
1.03 | 1.04 | 1.04 | 0.95 | |
Average Days of Payables |
154.26 | 177.65 | 147.98 | 168.70 | |
Days of Inventory on Hand |
440.85 | 453.91 | 427.53 | 463.51 | |
Tax Rate |
(0.18) | (0.20) | (0.19) | (0.20) | |
Research and Development Expense of Revenue |
21.13% | 20.46% | 19.53% | 18.32% | |
Selling, General and Administrative Expense of Revenue |
17.48% | 17.02% | 16.00% | 15.36% | |
Share Based Compensation of Revenue |
1.06% | 0.96% | 0.88% | 0.81% | |
Interest Coverage |
— | — | — | 83.46 | |
Operating CF/Net income |
0.87 | 0.81 | 0.81 | 1.05 | |
Depreciation/Fixed assets |
0.09 | 0.08 | 0.08 | 0.07 | |
Capex/Depreciation |
(3.58) | (3.93) | (4.24) | (4.71) | |
Revenue per Share |
66.25 | 72.64 | 80.77 | 89.27 | |
Operating CF per Share |
17.91 | 18.74 | 22.90 | 31.47 | |
Capex per Share |
(7.57) | (8.74) | (9.68) | (11.09) | |
Capex to Sales |
0.11 | 0.12 | 0.12 | 0.12 |
Columns are period end dates